Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055370 | Lung Injury NIH | 0.19 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 severe pneumonia.
Description: To determine the efficacy of ruxolitinib measured by overall survival
Measure: Overall survival Time: 28 days after registration into trialDescription: Assessment of the duration of ventilation support
Measure: Assessment of the duration of ventilation support Time: registration until 90 days after registration into trialDescription: Assessment of the extent of cytokine storm reduction (IL-6, CRP, ferritin)
Measure: cytokine storm Time: registration until 90 days after registration into trialDescription: To assess time on ICU
Measure: time on ICU Time: registration until 90 days after registration into trialDescription: To assess toxicity and safety of ruxolitinib treatment
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Time: registration until 90 days after registration into trialDescription: To assess the timeframe for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)
Measure: time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG) Time: registration until 90 days after registration into trialDescription: To assess pulmonary function (time point discharge from hospital) by CT scan
Measure: pulmonary function assessed by a CT scan Time: registration until 90 days after registration into trialDescription: To determine the efficacy of ruxolitinib measured by overall survival
Measure: overall survival Time: 90 days after registration into trialAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports